tsh biopharmoration Ltd (8432) - Total Assets
Based on the latest financial reports, tsh biopharmoration Ltd (8432) holds total assets worth NT$1.85 Billion TWD (≈ $58.35 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See tsh biopharmoration Ltd shareholders equity for net asset value and shareholders' equity analysis.
tsh biopharmoration Ltd - Total Assets Trend (2017–2024)
This chart illustrates how tsh biopharmoration Ltd's total assets have evolved over time, based on quarterly financial data.
tsh biopharmoration Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
tsh biopharmoration Ltd's total assets of NT$1.85 Billion consist of 70.8% current assets and 29.2% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 31.9% |
| Accounts Receivable | NT$200.66 Million | 10.9% |
| Inventory | NT$176.07 Million | 9.6% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how tsh biopharmoration Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 8432 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: tsh biopharmoration Ltd's current assets represent 70.8% of total assets in 2024, a decrease from 77.8% in 2017.
- Cash Position: Cash and equivalents constituted 31.9% of total assets in 2024, up from 30.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 10.9% of total assets.
tsh biopharmoration Ltd Competitors by Total Assets
Key competitors of tsh biopharmoration Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
China | CN¥15.34 Billion |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
|
China | CN¥15.32 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
tsh biopharmoration Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.94 | 5.39 | 8.89 |
| Quick Ratio | 4.32 | 4.60 | 8.00 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.04 Billion | NT$976.64 Million | NT$785.92 Million |
tsh biopharmoration Ltd - Advanced Valuation Insights
This section examines the relationship between tsh biopharmoration Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 31.6% |
| Total Assets | NT$1.84 Billion |
| Market Capitalization | $60.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values tsh biopharmoration Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: tsh biopharmoration Ltd's assets grew by 31.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for tsh biopharmoration Ltd (2017–2024)
The table below shows the annual total assets of tsh biopharmoration Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.84 Billion ≈ $58.04 Million |
+31.60% |
| 2023-12-31 | NT$1.40 Billion ≈ $44.10 Million |
-2.46% |
| 2022-12-31 | NT$1.44 Billion ≈ $45.21 Million |
+22.72% |
| 2021-12-31 | NT$1.17 Billion ≈ $36.84 Million |
-4.88% |
| 2020-12-31 | NT$1.23 Billion ≈ $38.73 Million |
-2.72% |
| 2019-12-31 | NT$1.26 Billion ≈ $39.82 Million |
+3.56% |
| 2018-12-31 | NT$1.22 Billion ≈ $38.45 Million |
-4.79% |
| 2017-12-31 | NT$1.28 Billion ≈ $40.38 Million |
-- |
About tsh biopharmoration Ltd
TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid … Read more